TP53 Y220H

CI-VAR-00004784Explore in graph →CIViC 3779

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease2unmapped disease
TP53 Y220H	(functional)	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10239 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic
TP53 Y220H	(functional)	Functional	D	Does Not Support Dominant Negative	3	submitted	EID10572 Yeast strain yIG397 was cultured to express both wild-type (WT) and mutant Y220H originally identified in CNS lymphoma. Should the mutant be dominant-negative (DN), TP53 will not bind and transactivat… (full text at CIViC) PMID 10519380 · Marutani et al., 1999 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.